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1ABSTRACT
The usefulness of somatotroph-specific aryl hydrocarbon receptor interacting protein 
knock out (sAIPKO) mice in developing therapeutics for GH secreting pituitary 
adenoma.
Woo Kyung Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Eun Jig Lee)
Acromegaly results from the chronic hypersecretion of GH, which primarily 
originates from GH secreting pituitary adenoma. Although 
transsphenoidaladenomectomy is the treatment of choice, some patients do not 
achieve biochemical remission after surgery and require medical treatment. However, 
there are not many available drugs due to the limitations of GH-secreting pituitary 
adenoma which include the poorly understood pathogenesis and lack of a proper 
animal model. Recently, Igenerated an animal model that develops GH secreting 
pituitary adenoma, which has the deletion of the aryl hydrocarbon receptor interacting 
protein (AIP) in somatotroph. To investigate the usefulness of somatotroph-specific 
AIP knock out (sAIPKO) mice in developing therapeutics for GH secreting pituitary 
2adenoma, I evaluated the biochemical effects of somatostatin analogs on sAIPKO 
mice. I generated sAIPKO mice using a Cre-loxp strategy.TwelvemalesAIPKO mice 
were assessed. The mice received a subcutaneous injection of 
octreotideLARorpasireotide LAR. Imeasured serum IGF-1 levels, body weight and
blood glucose levels three times a month. There were significant decreases in serum 
IGF-1 levels in the pasireotide group. However, serum IGF-1 levels intheoctreotide 
group showed a decreasing trend, although it was not statistically significant. Body 
weight in the pasireotide group significantly decreased on the 14th day, not on the 28th
day while there was no significant change in the octreotide group. Blood glucose 
levels in the pasireotide group increased significantly on 28thday.Pasireotide which is 
a multireceptor targeted somatostatin analog, had stronger inhibitory effects on 
biochemical activity in sAIPKO mice suggesting that this mouse model represent 
more aggressive GH secreting pituitary adenoma. Thus, this mouse model will be 
useful for drug development and efficacy evaluation in GH secreting pituitary 
adenoma.
-----------------------------------------------------------------------------------------------
Key words: Acromegaly, Aryl Hydrocarbon Receptor Interacting Protein, 
Somatostatin Analog
3The usefulness of somatotroph-specific aryl hydrocarbon receptor interacting 
protein knock out (sAIPKO) mice in developing therapeutics for GH secreting 
pituitary adenoma
Woo Kyung Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Eun Jig Lee)
I. INTRODUCTION
Acromegaly is characterized by chronic hypersecretion of growth hormone(GH), 
which primarily originates from a GH-secreting pituitary adenoma and induces the 
synthesis of insulin-like growth factor 1 (IGF-1). Elevated GH and IGF-1 levels cause 
metabolic dysfunction and somatic growth, resulting in significant morbidity and 
mortality for patients with acromegaly. As decreasing GH to <2.5ug/L and IGF-1 to 
normal levels significantly reduces mortality, the main treatment goal for acromegaly 
4is to control GH and IGF-1 levels. Additional goals are to reduce tumor size, preserve 
pituitary function and prevent recurrence.1-6
First-line treatment is usually transsphenoidal surgery; however, cure rates 
decrease with increasing tumor size, extrasellar extension, and cavernous sinus 
invasion7, and most patients with a macroadenoma require postsurgical medical 
treatment to achieve disease control.2 Long-acting somatostatin analogs are the 
cornerstone of medical therapy for acromegaly.8-10 However, many patients with 
acromegaly do not achieve biochemical control with the currently available 
somatostatin analogs.11
Pasireotide(SOM230) is a multireceptor-targeted somatostatin analog with high 
binding affinity for SSTR1, 2, 3 and SSTR5, including a 39- and 30-fold higher 
binding affinity for SSTR5 and SSTR1, respectively, than octreotide. Pasireotide 
showed a stronger inhibitory effect than octreotide on the secretion of GH, insulin-
like growth factor 1 (IGF1), ACTH, and corticosterone in animal models, suggesting 
that pasireotide has the potential to be an effective therapy in patients with active 
acromegaly and Cushing’s disease who are not responsive to octreotide.12,13
Germline mutations in the aryl hydrocarbon receptor interacting protein(AIP) 
gene have been found to occur in some patients with familial isolated pituitary 
adenoma (FIPA) and in sporadic young-onset pituitary adenomas.14-18Patients with 
AIP mutation are typically diagnosed with GH-secreting pituitary tumors 
(somatotropinomas, ~80% of cases) that cause acromegaly or gigantism.19,20 These 
5tumors tend to be diagnosed at a younger age and are larger and more aggressive, and 
the somatotroph adenomas do not appear to respond well to somatostatin analogs.14-18
AIP has properties consistent with a tumor suppressor gene, with loss of 
heterozygosity observed in pituitary tumor samples and in vitro data showing that
wild-type AIP attenuates cell proliferation, whereas mutant AIP loses this effect and 
AIP knockdown give rise to increased cell proliferation.16,21
There are not many available drugs due to the limitations of GH-secreting 
pituitary adenoma, which include the poorly understood pathogenesis and lack of 
proper animal model. For this reason, Irecently developed the animal model for GH-
secreting pituitary adenoma, which has the deletion of aryl hydrocarbon receptor 
interacting protein(AIP) in somatotroph. To investigate the usefulness of somatotroph-
specific AIP knock out (sAIPKO) mice in developing therapeutics for GH-secreting 
pituitary adenoma, I evaluated the effects of somatostatin analogs on the mice.
6II. MATERIALS AND METHODS
1. Compounds and formulations
OctreotideLAR, pasireotide LAR and the appropriate vehicles for thosewas 
provided by NovartisPharma AG (Basel, Switzerland). Octreotide LAR (320mg/kg, 
monthly dose) and Pasireotide LAR (320mg/kg, monthly dose) were reconstituted
with the appropriate vehicles and rapidly administeredsubcutaneously to the mice of 
each group according to the manufacturer’s details provided by Novartis.An IGF-1 
(insulin like growth factor-1) enzyme-linked immunosorbent assay (ELISA) kit was 
purchased from Abcam plc. (Cambridge, MA, USA).
2. Animals and treatments
I recently generated the mice which has the deletion of aryl hydrocarbon receptor 
interacting protein(AIP) in somatotroph. Mice lacking the AIP gene in pituitary 
somatotrophs were created by crossing mice with loxp sites flanking exons 5-7 of the 
AIP gene (AIP lox/lox)with transgenic mice expressing the Cre-recombinase under 
control of the rat growth hormone (GH) promotor (rGHp-Cretg). The targeted deletion 
of exons 5-7 of the AIP gene leads to deletion of the tetratricopeptide repeat (TPR) 
domains, an area involved in protein-protein interactions, and a region encompassing 
7a hot spot mutation site in the corresponding human genome. First, I measured body 
weight, blood glucose levels and serum IGF-1 levels to group twelve male mice to 
three groups equally according to them; control (n=4), octreotide-treated group (n=4), 
pasireotide-treated group (n=4). I collected blood from the mice by retroorbital sinus-
plexus sampling and measured the blood glucose levels by a glucometer (ARKRAY 
Factory, Inc., Kyoto, Japan). I also centrifuged it to obtain blood serum and measured 
serum IGF-1 levels by using IGF-1 mouse ELISA kit.After grouping, I injected 
carefully prepared octreotide LAR and pasireotide LAR into the back of the mice
once a month and checked the changes in body weight, blood glucose levels, and 
serum IGF-1 levels for each group.
3. IGF-1 mouse ELISA
The blood serum is collected on 14th and 28thday in addition to the first day and 
serum IGF-1 levels were determined using a competitive binding IGF-1 mouse 
ELISA kit according to the manufacturer’s instructions. The absorbance at 450 nm 
was measured and the serum IGF-1 levels for each sample were calculated using a 
standard curve generated with mouse IGF-1 reference solutions in the kit. The 
average of triplicate assays was calculated.
4. Statistical analysis
8Statistical analysis was performed by using Statistical Package for the Social 
Sciences software (IBM Corp., version 21, 1989-2012). Data with normal distribution 
were expressed as mean± SD. Paired t-test was used to compare serum IGF-1 levels 
before and after the drug treatment for each group. One-way ANOVA test was used to 
compare the baseline characteristics. Statistical significance was assigned for P < 0.05.
9III. RESULTS
1. Baseline characteristics of the sAIPKO mice
I used twelve male sAIPKO mice to evaluate the biochemical effects of 
somatostatin analogs in vivo. Their mean age is 61.7± 12.8 weeks. Igroupedthe mice 
to three groups; control, octreotide-treated group and pasireotide-treated group. As 
expected, there is no significant difference in the baseline characteristics between the 
three groups (Table 1).
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Table 1. Baseline characteristics of the mice in the study
Control (n=4) Octreotide (n=4) Pasireotide (n=4) p value†
Age (wks) 60.4±13.2 65.8±11.1 58.5±16.3 0.750
Body weight (kg) 35.8±4.1 36.4±4.0 38.5±3.5 0.604
Plasma Glucose 
(mg/dl)
170.3±25.7 137.5±34.0 163.8±16.8 0.233
Serum IGF-1 
(ng/ml)
107.1±43.9 98.1±20.6 119.2±29.9 0.674
IGF-1, Insulin-like growth factor-1
†: p value was measured by one-way ANOVA test
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2. The biochemical effects of somatostatin analogs
On both the 14th and 28th days, there were significant decreases in serum IGF-1 
levels in the pasireotide-treated group (p=0.016, p=0.008, respectively). However, 
serum IGF-1 levels in the octreotide-treated group showed a decreasing trend, 
although it was not statistically significant (Figure 1). Body weight in the pasireotide-
treated group significantly decreased on the 14th day (p=0.048), not on the 28th day 
while there was no significant change in the octreotide-treated group(Figure 2). There 
was no significant change of blood glucose levels in the pasireotide-treated group on 
the 14th day. However, blood glucose levels increased significantly on the 28th day
(p=0.027) in comparison with the 14th day. In contrast, there was no significant 
change of blood glucose levels in the octreotide-treated group (Figure 3).
12
Figure 1. The changes in serum IGF-1 levels.Pasireotide LAR (320mg/kg) and 
octreotide LAR (320mg/kg) were injected subcutaneously once a month to the mice 
for each group. Serum IGF-1 levels were measured using ELISA kit. Data are 
expressed as mean±SD (n=4). *P<0.05 vs. before the treatement of somatostatin 
analogs.
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Figure 2. The changes in body weight. Pasireotide LAR (320mg/kg) and octreotide 
LAR (320mg/kg) were injected subcutaneously once a month to the mice for each 
group.Data are expressed as mean±SD (n=4). *P<0.05 vs. before the treatement of 
somatostatin analogs.
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Figure 3. The changes inblood glucose levels. Pasireotide LAR (320mg/kg) and 
octreotide LAR (320mg/kg) were injected subcutaneously once a month to the mice 
for each group. Blood glucose levels were measured using a glucometer. Data are 
expressed as mean±SD (n=4). *P<0.05. 
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IV. DISCUSSION
This is the first study to show the biochemical effects of somatostatin analogs, 
especially pasireotide, on the mice which have the deletion of aryl hydrocarbon 
receptor interacting proteininsomatotroph (sAIPKO) and the results were similar 
tothose of previous studies based on human subjects.2,22With my results, the mouse 
model could be useful indeveloping therapeutics for GH-secreting pituitary tumor in 
the near future.
Mice in which Cre-recombinase is expressed in pituitary somatotrophs were 
developed by Luque et al.29 In these mice, 310 bp 5` of the initiation codon of the rat 
GH gene (rGHp) is used to target pituitary somatotrophs, and the resulting transgene, 
when expressed, permits selective Cre-mediated recombination of loxP-modified 
alleles in somatotroph-derived cells of the anterior pituitary. rGHp-Cretg/+; AIPlox/+
mice were obtained by crossing rGHp-Cretg/+ female mice with male AIP lox/lox mice. 
Interbreeding of rGHp-Cretg/+; AIPlox/+ mice produced homozygous disruption of the 
AIP gene in somatotrophs(rGHp-Cretg/+; AIPlox/lox).
rGHp-Cretg/+; AIPlox/lox(sAIPKO) mice exhibit normal embryonic and postnatal 
development, and display an unaltered distribution of anterior pituitary cell types. At 
48 weeks old age, sAIPKO mice had significantly larger body weight than 
AIPlox/loxlittermate mice (control). Overall, 40% of sAIPKO mice developed pituitary 
adenomas by 24 weeks of age and more than 80% developed pituitary adenomas by 
40 weeks. The incidences of pituitary tumor were similar among males and females. 
16
sAIPKO mice had no morphologic abnormality in other neuroendocrine organs. On 
histological examination, pituitary adenomas of sAIPKO mice appeared highly 
invasive.
Acromegaly is a chronic neuroendocrine disorder caused by excessive levels of 
growth hormone (GH) that drive the overproduction of insulin-like growth factor 1 
(IGF-1). In over 90% of cases, the origin of GH hypersecretion is a benign pituitary 
somatotroph adenoma.23 Clinical manifestations of the disease range from subtle acral 
enlargement to more serious consequences, such as diabetes mellitus, hypertension,
and respiratory and cardiac failure.24Furthermore, the rate of mortality in the patients 
with acromegaly who have elevated GH and IGF-1is greater than in the general 
population.4However, normalizing GH and IGF-1 levels restores the standardized 
mortality ratio in patients with acromegaly.3 Thus, the principal goals of treatment for 
acromegaly are to lower GH and normalize IGF-1 levels, and to prevent further tumor 
growth or even induce tumor shrinkage.25
Although the transsphenoidaladenomectomy is the treatment of choice, some 
patients do not achieve the biochemical remission after surgery and requiremedical 
treatment. However, there are not many available drugs due to the limitations of GH 
secreting pituitary adenoma which include the poorly understood pathogenesis and 
lack of proper animal models. I recently developed the mouse model which has the 
deletion of aryl hydrocarbon receptor interacting protein in somatotroph(sAIPKO)
using rGHp-Cretg mice. According to my previous data, almost 80% of the mice 
developed pituitary adenomas without morphologic abnormality in other 
17
neuroendocrine organs.In addition, the tumor appeared highly invasive on histological 
examination.
Pasireotide is distinguished from other somatostatin analogs by its binding profile. 
It has a broader binding spectrum, with high-affinity binding to receptors somatostatin 
receptor (SSTR) 2,3, and 5 and moderate affinity for SSTR1. The broadened 
selectivity of pasireotide, especially with regard to SSTR5, supports its clinical utility 
for somatotroph and corticotroph pituitary tumors along with other neuroendocrine 
tumors that express multiple SSTRs.26 Recently, Colao and collegues showed that 
pasireotide LAR demonstrated superior efficacy over octreotide LAR and is a viable 
new treatment option for acromegaly.2Gdelha and collegues also demonstrated that 
pasireotide provides superior efficacy compared with continued treatment with 
octreotide or lanreotide in patients with acromegaly who are inadequately controlled 
using first-generation somatostatin analogs.22My study showed that Pasireotide has 
stronger inhibitory effect on excessive IGF-1 levels on sAIPKO mice than octreotide
similar to previous clinical studies suggesting that the mouse model represents more 
aggressive GH secreting adenoma and might be useful to develop therapeutics for 
acromegaly in the near future.
Somatostatin is an inhibitor of both insulin and glucagon secretion by binding to 
SSTR2 and SSTR5 which are the predominantly expressed subtypes in human 
pancreatic islet cells.27 The predominant expression of SSTR5 on β cells and SSTR2 
on α cells was found in human islet cells.28Schmid and collegues suggested that
hyperglycemia caused by pasitreotidecould be explain by the expression pattern of 
18
SSTRs in rat pancreatic islet cells and demonstrated that this effects was transient 
with tachyphylaxis on rats.12 However, in my study, mice in the pasireotide-treated 
group developed hyperglycemia on the 28th day, not on the 14th day. This different 
result might be explained by metabolic differences or the difference of SSTR 
expression on pancreatic islet cells in sAIPKO mice which probably have GH 
secreting pituitary tumor, comparing with normal population. Recently, in clinical 
studies for pasireotide in patients with acromegaly, hyperglycemia and diabetes 
mellitus were more frequently reported in the groups on pasireotide.2,22
This study demonstrated that pasireotide LAR achieved greater suppression of 
IGF-1 than octreotide LAR on somatotroph specific AIPKO mice, while pasireotide 
LAR caused hyperglycemia more frequently than octreotide LAR on the mice similar 
to the previous studies for the drugs on patients with acromegaly suggesting that the 
mouse model could be a standard mouse model for aggressive GH secreting pituitary 
adenoma and be useful indevelopingnew therapeutics for the disease.
19
V. CONCLUSION
Pasireotide, which is a multireceptor targeted somatostatin analog, had a 
superiority over octreotide to control biochemical activity of GH secreting pituitary 
adenoma in sAIPKO mice, suggesting that this mouse model representsthe aggressive 
type of the disease. Thus, this mouse model is promising to be useful in developing
new drugs and evaluate the efficacy of them for GH secreting pituitary adenoma.
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ABSTRACT (IN KOREAN)
뇌하수체 선종 연구에 있어서 sAIPKO 마우스 모델의 유용성
<지도교수 이은직>
연세대학교 대학원 의학과
이우경
말단 비대증은 주로 성장호르몬 분비 뇌하수체 종양에 의해서 성장
호르몬이 과다 분비되어 생긴다.일차적 치료는 경접형골 수술이지만
어떤 환자들은 수술 후에도 성장호르몬 조절에 실패하여 약물치료를
필요로 한다.하지만,이러한 병은 드물고,이를 대표할 수 있는  모델
이 없어 병리기전이 잘 밝혀져 있지 않기 때문에 치료제 개발 연구
에 많은 제한이 있고 따라서 사용할 수 있는 약이 많지 않다.최근
우리는 성장자극세포에 특이적으로 AIP (aryl hydrocarbon receptor 
interacting protein)유전자를 삭제하여 성장호르몬 분비 뇌하수체
종양을 유발하는 쥐 모델 (sAIPKO)을 개발하였다.이러한 쥐 모델이
성장호르몬 분비 뇌하수체 종양 치료제 개발에 유용한 모델이 될 수
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있는지 확인하고자 이 쥐들에 현재 말단비대증 치료제로 알려져 있
는 소마토스타틴유사체들 (octreotide, pasireotide)을 투여한 뒤
그것들의 효과를 평가하였다.Octreotide를 투여한 군에서는 Insulin 
like growth factor 1(IGF-1)가 줄어들지만 통계학적으로 유의하지
않는 반면,Pasireotide를 투여한 군에서는 IGF-1이 통계학적으로 유
의하게 줄어들었다.그리고 Octreotide를 투여한 군에서 혈중 혈당
수치의 변화는 없었던 반면,Pasireotide를 투여한 군에서는 혈중 혈
당 수치가 4주뒤 유의있게 증가된 것을 알 수 있었다.여러 소마토스
타틴 수용체에 강하게 작용하는 pasireotide는 sAIPKO쥐 모델에서
생화학적 조절에 있어서 octreotide에 비해 두드러진 효과를 보였다.
이는 sAIPKO mouse가 좀 더 공격적인 성장호르몬 분비 종양을 반영
할 수 있다는 것을 시사하고,따라서이 쥐 모델은 향후 성장호르몬
분비 뇌하수체 종양의 치료제 개발에 있어서 유용할 것이다.
---------------------------------------------------------------
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